GlassScriptPhysician profile
Kathryn L Murphy
NPI 1689082323
$8,972.55
in general payments reported to CMS, 2019-2025
33 companies · $2,961 in 2025
The $2,961 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,356 · 2022: $1,576 · 2023: $1,985 · 2024: $1,096 · 2025: $2,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,040.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,281.34 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,180.27 | 2021-2025 | Ajovy |
| Lilly USA, LLC | $536.88 | 2021-2025 | Emgality, Reyvow, Zepbound |
| Amgen INC. | $532.44 | 2021-2023 | Aimovig |
| Pfizer INC. | $509.96 | 2023-2025 | |
| Tonix Medicines, INC. | $478.59 | 2024-2025 | Zembrace Symtouch |
| Currax Pharmaceuticals LLC | $476.03 | 2021-2024 | Onzetra Xsail, Contrave |
| Lundbeck LLC | $446.81 | 2021-2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $364.38 | 2023-2025 | Ztlido, Elyxyb |
| Axsome Therapeutics, INC. | $350.74 | 2025 | Symbravo |
| Impel Pharmaceuticals INC. | $254.25 | 2023 | Trudhesa |
| Impel Pharmaceuticals LLC | $237.37 | 2024-2025 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $166.28 | 2021 | |
| Upsher-Smith Laboratories LLC | $159.65 | 2021-2023 | |
| Ucb, INC. | $159.20 | 2021-2025 | Nayzilam, Briviact |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $141.32 | 2022 | |
| Springworks Therapeutics, INC. | $109.60 | 2025 | Gomekli |
| Supernus Pharmaceuticals, INC. | $91.99 | 2021-2022 | |
| Sk Life Science, INC. | $58.19 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $55.32 | 2021 | |
| Azurity Pharmaceuticals, INC. | $54.73 | 2023-2024 | Eprontia, Zonisade |
| Ibsa Pharma INC. | $50.88 | 2025 | Tirosint, Flector, Licart |
| Novo Nordisk INC | $50.00 | 2024-2025 | Wegovy |
| Novocure INC. | $45.25 | 2022-2023 | Optune |
| Csl Behring | $27.72 | 2025 | Hizentra |
| Eisai INC. | $25.48 | 2025 | |
| Octapharma USA, INC. | $24.78 | 2024 | Panzyga |
| Averitas Pharma INC. | $22.29 | 2025 | Qutenza |
| Ipsen Biopharmaceuticals, INC | $19.25 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.97 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.92 | 2022 | |
| Ge Healthcare | $14.34 | 2023 | |
| Sun Pharmaceutical Industries INC. | $14.33 | 2023 | Winlevi, Absorica Ld |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.